3. Significant Strategic Drug Development Collaborations
|9 Months Ended|
Sep. 30, 2015
|Research and Development [Abstract]|
|Significant Strategic Drug Development Collaborations||
The Company had various research, development, license and supply agreements with Baxter Healthcare SA and Baxter Healthcare Corporation (together referred to as Baxter). During June 2015, in connection with the separation of its biopharmaceuticals business to form Baxalta Incorporated (Baxalta), Baxter assigned all of its rights and obligations under its existing agreement with the Company to Baxalta. Other than, with respect to the assignment to Baxalta, the Companys agreements with Baxter will continue with full force and effect. In addition, the Company has various research, development, license and supply agreements with SynBio LLC (SynBio), Serum Institute of India (Serum Institute) and OJSC Pharmsynthez (Pharmsynthez). The Company and its collaborative partners continued to engage in research and development activities with no resultant commercial products through September 30, 2015. No amounts were recognized as revenue related to these agreements during the nine months ended September 30, 2015 or 2014.
The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
Reference 1: http://www.xbrl.org/2003/role/presentationRef